Compare OFIX & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFIX | TECX |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | 60 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.3M | 554.1M |
| IPO Year | 1998 | N/A |
| Metric | OFIX | TECX |
|---|---|---|
| Price | $12.24 | $27.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.25 | ★ $75.20 |
| AVG Volume (30 Days) | ★ 211.9K | 187.0K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | N/A |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $6.22 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $14.39 |
| 52 Week High | $16.99 | $35.99 |
| Indicator | OFIX | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 48.69 | 42.16 |
| Support Level | $10.94 | $17.71 |
| Resistance Level | $12.99 | $31.88 |
| Average True Range (ATR) | 0.42 | 1.47 |
| MACD | 0.01 | -0.39 |
| Stochastic Oscillator | 45.83 | 19.78 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.